| Nov 15 |
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
|
| Nov 15 |
Q3 2024 BioXcel Therapeutics Inc Earnings Call
|
| Nov 14 |
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 14 |
BioXcel Therapeutics GAAP EPS of -$0.32 beats by $0.23, revenue of $0.21M misses by $1.12M
|
| Nov 14 |
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 13 |
BioXcel Therapeutics Q3 2024 Earnings Preview
|
| Nov 12 |
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
|
| Nov 8 |
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
|
